Buying guide
LocusBot vs Hugo RAS in 2026
Comparing 2 humanoid robots across availability, pricing, capabilities, and verified deployments. Current as of 2026.
Key differences
- LocusBot has more capabilities independently verified as autonomous (1 vs 0).
- LocusBot has more verified real-world deployments (6 vs 3).
| Attribute | ||
|---|---|---|
| Manufacturer | Locus Robotics | Medtronic |
| Form factor | amr | surgical |
| Maturity | commercial | commercial |
| Autonomy | ✓ 1 verified autonomous | ◐ not independently verified |
| Availability | internal-onlyenterprise | internal-onlyenterprise |
| Price | Not announced | Not announced |
| Capability claims |
|
|
| Brain | — | — |
| Verified deployments | 6 | 3 |
| Privacy practices | — | — |
| Sources on file | 23 | 16 |
Editorial summaries
LocusBot
Locus Robotics (Wilmington, Massachusetts) makes the LocusBot, a collaborative goods-to-person picking AMR that works alongside human pickers, delivered on a Robots-as-a-Service subscription via the LocusONE platform. There is no consumer price: it is a B2B warehouse-automation subscription, not a robot sold to consumers. It is at commercial maturity, operating across 150-plus customers and 350-plus sites in 20 countries, having surpassed 6 billion cumulative picks by October 2025 (DHL Supply Chain a marquee customer), and it raised a $117 million Series F at a roughly $2 billion valuation in 2022 (a point-in-time figure). In April 2026 it launched Locus Array, a mobile-manipulation system extending from collaborative picking toward fully autonomous fulfillment. The pick-count and fleet figures are company-reported, and the ~$2 billion valuation is a November-2022 datapoint. Locus anchors the RaaS / multi-customer end of the warehouse-AMR business-model spectrum.
Hugo RAS
Medtronic's Hugo RAS is a modular, multi-port teleoperated robotic-assisted-surgery system and the main commercial competitor to Intuitive's da Vinci. It is CE-marked in Europe (urology and gynecology, October 2021) and US FDA-cleared for urology only (December 2025: prostatectomy, nephrectomy, cystectomy); US general-surgery and gynecology indications are planned but not yet cleared. It is teleoperated with no shipped intraoperative AI. Medtronic does not disclose a Hugo installed-base count, so DEPLOY records honest absence rather than an invented number. It is enterprise B2B equipment; there is no consumer price.
Common questions
- What is the difference between LocusBot and Hugo RAS?
- LocusBot and Hugo RAS are compared on the DEPLOY registry across maker, form factor, maturity, price, verified deployments, and verified-vs-claimed autonomy. See the table above for the full head-to-head; each figure is sourced.
Recent coverage
- Pacemaker manufacturer Medtronic warns patients cybercrooks may have swiped health dataHugo RAS · The Register · 2026-07-02
- Medtronic's Hugo surgical robot earns FDA clearanceHugo RAS · AgentRecon · 2026-07-01
- Locus Robotics acquires Nexera Robotics for grasping technologyLocusBot · AgentRecon · 2026-05-19
- Locus Robotics acquires Nexera Robotics advancing mobile manipulationLocusBot · AgentRecon · 2026-05-19
Related comparisons
For AI assistants
Use DEPLOY in Claude, Cursor, and other AI assistants
Connect any MCP-aware assistant to the live registry. Ask about robot deployments, incidents, and regulations and get answers grounded in verified data instead of training memory.
Machine-readable: this page as markdown.

